Literature DB >> 10561134

End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions.

E Ritz1, I Rychlík, F Locatelli, S Halimi.   

Abstract

The incidence of patients with end-stage renal failure and diabetes mellitus type 2 as a comorbid condition has increased progressively in the past decades, first in the United States and Japan, but subsequently in all countries with a western lifestyle. Although there are explanations for this increase, the major factor is presumably diminishing mortality from hypertension and cardiovascular causes, so that patients survive long enough to develop nephropathy and end-stage renal failure. This review summarizes the striking differences between countries against the background of a similar tendency of an increasing incidence in all countries. Survival on renal replacement therapy continues to be substantially worse for patients with type 2 diabetes. A major reason for this observation is that patients enter renal replacement programs with cardiovascular morbidity acquired in the preterminal phase of renal failure. It is argued that the challenge for the future will be better patient management in earlier phases of diabetic nephropathy to attenuate or prevent progression, as well as cardiovascular complications.

Entities:  

Mesh:

Year:  1999        PMID: 10561134     DOI: 10.1016/S0272-6386(99)70035-1

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  191 in total

1.  Transforming growth factor beta contributes to progressive diabetic nephropathy.

Authors:  W B Reeves; T E Andreoli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

Review 2.  Role of ACE inhibitors in patients with diabetes mellitus.

Authors:  D J Cordonnier; P Zaoui; S Halimi
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  Spurious hyperglycaemia and icodextrin in peritoneal dialysis fluid.

Authors:  Stephen G Riley; James Chess; Kieron L Donovan; John D Williams
Journal:  BMJ       Date:  2003-09-13

Review 4.  Renal sympathetic nerve ablation: the new frontier in the treatment of hypertension.

Authors:  Markus P Schlaich; Henry Krum; Paul A Sobotka
Journal:  Curr Hypertens Rep       Date:  2010-02       Impact factor: 5.369

Review 5.  Oxidative stress in diabetic nephropathy.

Authors:  N Kashihara; Y Haruna; V K Kondeti; Y S Kanwar
Journal:  Curr Med Chem       Date:  2010       Impact factor: 4.530

Review 6.  Anemia and diabetic nephropathy.

Authors:  Eberhard Ritz
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

Review 7.  Inflammation and diabetic nephropathy.

Authors:  Carmen Mora; Juan F Navarro
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

8.  End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry.

Authors:  X L Yang; W Y So; A P S Kong; P Clarke; C S Ho; C W K Lam; M H L Ng; R R Lyu; D D Yin; C C Chow; C S Cockram; P C Y Tong; J C N Chan
Journal:  Diabetologia       Date:  2006-08-30       Impact factor: 10.122

Review 9.  Update on the treatment of type 2 diabetes mellitus.

Authors:  Juan José Marín-Peñalver; Iciar Martín-Timón; Cristina Sevillano-Collantes; Francisco Javier Del Cañizo-Gómez
Journal:  World J Diabetes       Date:  2016-09-15

10.  Acetylshikonin from Zicao ameliorates renal dysfunction and fibrosis in diabetic mice by inhibiting TGF-β1/Smad pathway.

Authors:  Zezhao Li; Zhen Hong; Zhiqing Peng; Yongcai Zhao; Rusheng Shao
Journal:  Hum Cell       Date:  2018-03-17       Impact factor: 4.174

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.